July 30, 2018 Washington, DC, – The Kidney Cancer Research Alliance(KCCure) responded to the Committee for Medicinal Products for Human Use (CHMP) recommendation against approval by the European Medicines Agency (EMA) of ipilimumab (Yervoy) combined with nivolumab (Opdivo) for the first line treatment of high and intermediate risk metastatic renal cell carcinoma (kidney cancer). The question of si...
Katherine Battle was nine when her dad died of kidney cancer. In this essay she writes about loss, remembrance and above all things - enduring love. The past can't be changed - but her voice gives us all hope for the future.
"I realize that there is no avoiding death from this disease, so I plan for its eventuality but I refuse to stop living. Cancer does not define me." James is a stage 4 kidney cancer survivor and this is is his story.
Julie is a stage 4 kidney cancer survivor and author of the blog: Julie's Not Dying Today. Her latest post about working with Sonya Owens, a Licensed Clinical Social Worker on managing emotional aspects of cancer is something that all patients can benefit from. Thank you Julie for educating and inspiring!
When it comes to kidney cancer, a tie isn’t good enough. We need a win. Join our month-long fundraising effort, No Tie July, and help us raise one year of life-saving research funding in just one month.
As members of the International Kidney Cancer Coalition (IKCC), KCCure is a proud partner and participant of the second-annual World Kidney Cancer Q&A Day.
KCCure recently attended ASCO - the world's largest cancer research conference. Learn more below on why everyone in the kidney cancer world is talking about CARMENA.
During ASCO, new data was presented from the “CARMENA” trial showing that overall survival for metastatic patients was not improved by performing a nephrectomy (or removing the primary tumor). This is a controversial question and one that is being debated by many physicians. We want to include the patient voice in that debate. Please take a few minutes to fill out this brief survey ...
For the second year in a row, KCCure represented kidney cancer patients at the annual meeting for the American Urological Association. This year, KCCure was instrumental in planning for the meeting by serving on the AUA Steering Committee for Patient Advocacy Efforts.
Kidney Cancer Research Alliance (KCCure) President Dena Battle has been elected to represent patients on the National Cancer Institute's Genitourinary Steering Committee(GUSC). The primary focus of the committee is to address design prioritization and evaluation of concepts for phase 2 and 3 clinical trials in GU cancers. Her term is effective May 25, 2018 and will last through May 2021.
“Today’s decision by the FDA is a game-changer for patients and physicians managing advanced kidney cancer,” said Hans Hammers M.D., Ph.D., KCCure co-founder and senior co-author of the clinical study for the combination.
Deb Gottsleben is co-chair of the KCCure Patient Advisory Board and a passionate advocate for better care for patients with newly diagnosed renal tumors.